Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

NCT: NCT03243019 · RECRUITING

NCT IDNCT03243019
StatusRECRUITING
Start Date2018-06-25
SponsorUniversity Hospital, Lille (OTHER)
First posted
Last updated

Brief Summary

To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑